Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.

Savarirayan R, Wilcox WR, Harmatz P, Phillips J 3rd, Polgreen LE, Tofts L, Ozono K, Arundel P, Irving M, Bacino CA, Basel D, Bober MB, Charrow J, Mochizuki H, Kotani Y, Saal HM, Army C, Jeha G, Qi Y, Han L, Fisheleva E, Huntsman-Labed A, Day J

Open source

DOI: 10.1016/s2352-4642(23)00265-1
Published: 2024 Jan
Container: The Lancet. Child & adolescent health
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-4642-23-00265-1,
  title = {Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.},
  author = {Savarirayan R and Wilcox WR and Harmatz P and Phillips J 3rd and Polgreen LE and Tofts L and Ozono K and Arundel P and Irving M and Bacino CA and Basel D and Bober MB and Charrow J and Mochizuki H and Kotani Y and Saal HM and Army C and Jeha G and Qi Y and Han L and Fisheleva E and Huntsman-Labed A and Day J},
  year = {2024},
  journal = {The Lancet. Child \& adolescent health},
  doi = {10.1016/s2352-4642(23)00265-1},
  url = {https://doi.org/10.1016/s2352-4642(23)00265-1}
}

RIS

TY  - JOUR
TI  - Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.
AU  - Savarirayan R
AU  - Wilcox WR
AU  - Harmatz P
AU  - Phillips J 3rd
AU  - Polgreen LE
AU  - Tofts L
AU  - Ozono K
AU  - Arundel P
AU  - Irving M
AU  - Bacino CA
AU  - Basel D
AU  - Bober MB
AU  - Charrow J
AU  - Mochizuki H
AU  - Kotani Y
AU  - Saal HM
AU  - Army C
AU  - Jeha G
AU  - Qi Y
AU  - Han L
AU  - Fisheleva E
AU  - Huntsman-Labed A
AU  - Day J
PY  - 2024
JO  - The Lancet. Child & adolescent health
DO  - 10.1016/s2352-4642(23)00265-1
UR  - https://doi.org/10.1016/s2352-4642(23)00265-1
ER  -

APA

R, S., WR, W., P, H., 3rd, P. J., LE, P., L, T., K, O., P, A., M, I., CA, B., D, B., MB, B., J, C., H, M., Y, K., HM, S., C, A., G, J., Y, Q., L, H., E, F., A, H., & J, D. (2024). Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Child & adolescent health. https://doi.org/10.1016/s2352-4642(23)00265-1

Source records

pubmed · retrieved 2026-09-26T21:52:33.819Z
europe-pmc · retrieved 2026-09-26T21:52:33.832Z